CAS: 1704-62-7; 2-(2-(Dimethylamino)Ethoxy)Ethanol

相似化合物

136533-09-0 1628679-52-6 2741-30-2

上下游产品

oxirane 2-(N,N-dimethylamino)ethanol dimethyl amine 2-(2-Chloroethoxy)ethanol dimethoxanate hydr°Chloride 1-(2-dimethylamino-ethoxy)-2-methacryloyloxy-ethane [2-(2-Di-p-tolylmethoxy-ethoxy)-ethyl]-dimethyl-amine Dimethyl-{2-[2-(phenyl-p-tolyl-methoxy)-ethoxy]-ethyl}-amine

(2-Dimethylamino-Ethoxy)-Acetic Acid Ethyl Ester置于lithium Aluminium Tetrahydride体系中,用 乙醚 用作溶剂,化学反应生成N,N-二甲基氨乙基乙二醇
参考文献:杂原子取代的甲基基团和连接到 1,3-二氧戊环的 C-2 上的乙烯基基团 (Cr2=cr-) 对 Alh2Cl,Alh3 或 Lialh4 对 1,3-二氧戊环氢解的难易和方向的影响
标题:杂原子取代的甲基基团和连接到 1,3-二氧戊环的 C-2 上的乙烯基基团 (Cr2=cr-) 对 Alh2Cl,Alh3 或 Lialh4 对 1,3-二氧戊环氢解的难易和方向的影响
摘要:2-甲基-1,3-二氧戊环的甲基上的杂原子取代基阻碍了 2-取代的 1,3-二氧戊环的醚溶液的 Alh2Cl 的氢解速率.杂原子在降低氢解容易度方面的有效性是 H < S < O < Br < Nr2.这种延迟被认为是由于杂原子的电负性和/或一些 Alh2Cl 与杂原子的配位引起的过渡态不稳定导致中间氧碳离子.Alh2Cl 或 Alh3 在室温下乙醚中将 2-乙烯基-或 2-[烷基(或芳基)取代的乙烯基]-1,3-二氧戊环还原为仅 β,γ-不饱和烷基 β-羟乙基醚,预期产物是氢阴离子加成到 C-2 1,3-二氧戊环.
Doi:10.1139/v71-422

专利信息

专利号:US-2004242897-A1
优先权日:2002-07-31
标题 :Universal support media for synthesis of oligomeric compounds
发明人：GUZAEV ANDREI P; MANOHARAN MUTHIAH
摘要:Compounds for the synthesis of oligomeric compounds, particularly oligonucleotides and oligonucleotide mimetics, are provided. In addition, methods for functionalizing a support medium with a first monomeric subunit and methods for the synthesis of oligomeric compounds utilizing the novel compounds bound to support media are provided.

专利号:US-6653468-B1
优先权日:2002-07-31
标 题 :Universal support media for synthesis of oligomeric compounds
发明人：GUZAEV ANDREI P; MANOHARAN MUTHIAH
权利人:ISIS PHARMACEUTICALS INC
摘要:Compounds for the synthesis of oligomeric compounds, particularly oligonucleotides and oligonucleotide mimetics, are provided. In addition, methods for functionalizing a support medium with a first monomeric subunit and methods for the synthesis of oligomeric compounds utilizing the novel compounds bound to support media are provided.

专利号:US-2008119645-A1
优先权日:2004-05-05
标题 :Amidites and Methods of Rna Synthesis
发明人：GRIFFEY RICHARD H; ROSS BRUCE S; SONG QUANLAI
权利人:ISIS PHARMACEUTICALS INC
摘要:The present invention is directed to amidites useful in the synthesis of oligonucleotides comprising at least one RN moiety, and to methods of using such amidites in the synthesis of such oligonucleotides. The inventive amidites possess surprising coupling efficiency as compared to prior art amidites, while providing convenient intermediates in the synthesis of oligonucleotides possessing at least one free 2′-OH moiety.

专利号:US-2014378538-A1
优先权日:2011-12-14
标 题:Methods of responding to a biothreat
发明人：BANCEL STEPHANE
权利人:MODERMA THERAPEUTICS INC
摘要:The present disclosure provides for devices, in particular mobile devices, which may be used in the synthesis of modified nucleic acid molecules, in particular modified mRNA molecules. The device for making the modified nucleosides, modified nucleotides and modified nucleic acids (e.g., mRNA) disclosed herein may be mobile devices comprising at least one sample block for insertion of one or more sample vessels, a device base with electronic control units for the sample block, a voltage supply, and one or more reagent(s) for the synthesis of at least one nucleic acid.

专利号:US-2023220379-A1
优先权日:2021-09-24
标 题 :HIGH PURITY gRNA SYNTHESIS PROCESS
发明人：DAS RAJAT; SANKARAN GANAPATHY
权利人:CRISPR THERAPEUTICS AG
摘要:The present disclosure relates to methods, compositions and kits for synthesizing moderate length RNAs (mlRNAs, including gRNAs) by splint-mediated ligation of RNA fragments. The synthesis of moderate length RNAs can be followed by DNase treatment. In some embodiments, splint DNA oligonucleotides that are no longer than 32 nucleotides are used.

专利号:US-7038037-B2
优先权日:2002-06-20
标题 :Method for sequential support-bound synthesis of conjugated oligomeric compounds
发明人：MAIER MARTIN A; GUZAEV ANDREI P; MANOHARAN MUTHIAH
权利人:ISIS PHARMACEUTICALS INC
摘要:A sequential support-bound synthesis method is disclosed for preparing a conjugated oligomeric compound, preferably a PNA-peptide conjugate or an oligonucleotide-peptide conjugate, using a bridging molecule having at least two N-protecting amino groups. A conjugated oligomeric compound for therapeutic or prophylactic delivery is also disclosed.